Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023
Financial highlights Direct MagnetOs sales grew by 163% to CHF 31.7 million in 2023, climbing from CHF 12.1 million…
Financial highlights Direct MagnetOs sales grew by 163% to CHF 31.7 million in 2023, climbing from CHF 12.1 million…
MagnetOs™ Granules becomes the third product in the MagnetOs portfolio to receive FDA clearance to market for inter…
. New level 1 data from the MAXA Clinical Trial comparing standalone MagnetOs to the gold standard autograft in the ch…
. Financial highlights Direct sales of MagnetOs rose 75% from CHF 6.9 million to CHF 12.1 million in 2022. Total reven…
Raynet, global software vendor with market-leading solutions and managed service provider in the field of Enterprise Sof…
Raynet, global agierender Softwarehersteller mit marktführenden Lösungen und Managed Service Provider im Bereich Enterpr…
Financial highlights CHF 29.4 million cash & cash equivalents, trade and other receivables as of June 30, 2022 Product…
Soft, moldable formulation that is ready to use with no need for thawing or mixing Becomes third commercial MagnetOs pro…
Clearance as a bone void filler for use in the posterolateral spine Third FDA clearance for MagnetOs in the last 7 m…
MagnetOs U.S. YTD sales increase 119% in 2021 compared to 2020 Kuros expanding MagnetOs range to increase perioperat…